Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $35.2 million.

  • Ligand Pharmaceuticals' Depreciation & Amortization (CF) fell 8.06% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.2 million, marking a year-over-year decrease of 3.77%. This contributed to the annual value of $35.2 million for FY2024, which is 3.51% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $35.2 million for FY2024, which was down 3.51% from $36.5 million recorded in FY2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Depreciation & Amortization (CF) peaked at $51.5 million during FY2022, and registered a low of $25.7 million during FY2020.
  • Over the past 3 years, Ligand Pharmaceuticals' median Depreciation & Amortization (CF) value was $36.5 million (recorded in 2023), while the average stood at $41.1 million.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Depreciation & Amortization (CF) surged by 98.79% in 2021 and then declined by 29.13% in 2023.
  • Yearly analysis of 5 years shows Ligand Pharmaceuticals' Depreciation & Amortization (CF) stood at $25.7 million in 2020, then soared by 98.79% to $51.1 million in 2021, then grew by 0.91% to $51.5 million in 2022, then decreased by 29.13% to $36.5 million in 2023, then declined by 3.51% to $35.2 million in 2024.